Product Pipeline
  • 2010

    8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...

    Read More >

  • Meet us

    The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...

    Read More >

Product Pipeline

Zealand's Pipeline comprises 1 compound in phase III,  1 compound in phase II, 3 compounds in phase I, and  2 compounds in pre-clinical development.
The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth) and of ZP120 for acute heart failure has been terminated after Phase II clinical trials. The development of ZP2435 for treatment of obesity was terminated in preclinical development.

Pipeline Graph

The following table summarizes the status of Zealand Pharma's current product pipeline.


Product Candidate

Indication

Commercial Partner

Status

Lixisenatide/ZP10

Type 2 diabetes

  

Sanofi-aventis

Completed enrollment of all Phase III studies by Q1, 2010 

Combination of Lixisenatide/ZP10 
and Lantus®

Type 2 diabetes

  

Sanofi-aventis

Finalized Phase I by Q1, 2010

 ZP1480

 Post-surgical Organ  Failure

 Action Pharma

 Phase II – initiated in 2008

ZP1846

Chemotherapy-induced diarrhea

Helsinn Healthcare

Phase I – safety and tolerability study in colorectal patients initiated 2010

Danegaptide/ZP1609 

Atrial Fibrillation     

Wyeth (now Pfizer) 

Phase I - single dose safety and tolerability trial finalized 2009

ZP1848

Inflammatory Bowel Disease

 

Phase I – single dose, safety and tolerability trial finalized Q3, 2010

ZP2307

Osteoporosis

 

Preclinical

ZP2929

Type 2 diabetes and 
Obesity

 

Preclinical



To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.